Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. April 2009 09:15 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Halts RING Trial in Advanced Gastrointestinal Stromal Tumors

-- Decision Based On Recommendation Received Tuesday Night From Independent Data Monitoring Committee -- -- Infinity Reaffirms Commitment to Hsp90 Development and Cash ...
15. April 2009 03:01 ET | Quelle: BiPar Sciences

Sanofi-aventis to Acquire BiPar Sciences, a US Biopharmaceutical Company

BRISBANE, Calif. and PARIS, April 15, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) announced today that it has signed a binding agreement for the acquisition of BiPar Sciences,...
14. April 2009 08:20 ET | Quelle: Marshall Edwards, Inc.

Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards, Inc., (NASDAQ: MSHL) today announced that it will be undertaking an un-blinded analysis of the data from its...
14. April 2009 08:00 ET | Quelle: Vyteris, Inc.

Vyteris and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs

FAIR LAWN, NJ--(Marketwire - April 14, 2009) - Vyteris, Inc. (OTCBB: VYTR), developer of the first FDA-approved active transdermal drug delivery system and a leader in active transdermal drug...
30. März 2009 06:30 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Initiates International Phase 2 Trial of IPI-504 in Combination With Herceptin(r) in Patients With HER2-Positive Breast Cancer

CAMBRIDGE, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the initiation of a...
24. März 2009 10:10 ET | Quelle: Cutting Edge Information

Small Companies Must Use Business Development Best Practices to Garner Licensing Agreements With Pharma, Says Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwire - March 24, 2009) - Just a few months ago, biotech companies were set to overcome the lack of available venture capital through big pharma acquisitions. ...
20. März 2009 05:00 ET | Quelle: BioInvent International AB

KALLELSE TILL ÅRSSTÄMMA I BIOINVENT INTERNATIONAL AB

KALLELSE TILL ÅRSSTÄMMA I BIOINVENT INTERNATIONAL AB Aktieägarna i BioInvent International AB (publ), org nr 556537-7263, kallas härmed till årsstämma tisdagen den 21 april 2009, klockan 16.00 på...
05. März 2009 20:16 ET | Quelle: Dow Jones Indexes

Dow Jones Indexes Announces Dow Jones Country Titans and Dow Jones Select Dividend Indexes Regular Annual and Quarterly Review Results

NEW YORK, March 5, 2009 (GLOBE NEWSWIRE) -- Dow Jones Indexes, a leading global index provider, today announced the results of the regular annual review of the Dow Jones Country Titans Indexes and Dow...
05. März 2009 08:15 ET | Quelle: Cutting Edge Information

Eli Lilly's Prasugrel Approved in EU, Needs Aggressive Promotional Campaign to Compete With Plavix, Suggests New Study by Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwire - March 5, 2009) - Since Eli Lilly's Prasugrel has received EU approval, Plavix will need to brace itself for strong competition for market share. Generating...
27. Februar 2009 05:00 ET | Quelle: BioInvent International AB

BioInvent presenterar positiva prekliniska data för BI-505 vid behandling av multipelt myelom

BioInvent presenterar positiva prekliniska data för BI-505 vid behandling av multipelt myelom Antikropp riktad mot ICAM-1 inducerar tumörcellsdöd in vivo Lund, Sverige - 27 februari 2009 -...

Vorherige Seite